Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Strengths and Weaknesses of Docking Simulations in the SARS-CoV-2 Era: the Main Protease (Mpro) Case Study
Manuel A. Llanos, Melisa E. Gantner, Santiago Rodrı́guez, et al.
Journal of Chemical Information and Modeling (2021) Vol. 61, Iss. 8, pp. 3758-3770
Open Access | Times Cited: 42

Showing 1-25 of 42 citing articles:

Methodology-Centered Review of Molecular Modeling, Simulation, and Prediction of SARS-CoV-2
Kaifu Gao, Rui Wang, Jiahui Chen, et al.
Chemical Reviews (2022) Vol. 122, Iss. 13, pp. 11287-11368
Open Access | Times Cited: 58
Computer-assisted drug repurposing for thymidylate kinase drug target in monkeypox virus
Amar Ajmal, Arif Mahmood, Chandni Hayat, et al.
Frontiers in Cellular and Infection Microbiology (2023) Vol. 13
Open Access | Times Cited: 26
A Review of the Current Landscape of SARS-CoV-2 Main Protease Inhibitors: Have We Hit the Bullseye Yet?
Guillem Macip, Pol Garcia‐Segura, Júlia Mestres‐Truyol, et al.
International Journal of Molecular Sciences (2021) Vol. 23, Iss. 1, pp. 259-259
Open Access | Times Cited: 41
Drug repurposing in psoriasis, performed by reversal of disease-associated gene expression profiles
Faheem Ahmed, Son Gi Ho, Anupama Samantasinghar, et al.
Computational and Structural Biotechnology Journal (2022) Vol. 20, pp. 6097-6107
Open Access | Times Cited: 32
Computer-aided drug design of novel nirmatrelvir analogs inhibiting main protease of Coronavirus SARS-CoV-2
Kateryna Lohachova, Anastasiia S . Sviatenko, Alexander Kyrychenko, et al.
Journal of Applied Pharmaceutical Science (2024)
Open Access | Times Cited: 6
Evaluating the structure-based virtual screening performance of SARS-CoV-2 main protease: A benchmarking approach and a multistage screening example against the wild-type and Omicron variants
Noha Galal, Botros Y. Beshay, Omar Soliman, et al.
PLoS ONE (2025) Vol. 20, Iss. 2, pp. e0318712-e0318712
Open Access
Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics
Matteo Pavan, Stefano Moro
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4401-4401
Open Access | Times Cited: 13
Epicatechin is a promising novel inhibitor of SARS-CoV-2 entry by disrupting interactions between angiotensin-converting enzyme type 2 and the viral receptor binding domain: A computational/simulation study
Mohammed Baqur S. Al‐Shuhaib, Hayder O. Hashim, Jafar M. B. Al‐Shuhaib
Computers in Biology and Medicine (2021) Vol. 141, pp. 105155-105155
Open Access | Times Cited: 29
Computational molecular interaction between SARS-CoV-2 main protease and theaflavin digallate using free energy perturbation and molecular dynamics
Manish Manish, Smriti Mishra, Ayush Anand, et al.
Computers in Biology and Medicine (2022) Vol. 150, pp. 106125-106125
Open Access | Times Cited: 19
Bioengineered amyloid peptide for rapid screening of inhibitors against main protease of SARS-CoV-2
Dongtak Lee, Hyo Gi Jung, Dongsung Park, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 3
Computational Models of Claudin Assembly in Tight Junctions and Strand Properties
Sarah McGuinness, Samaneh Sajjadi, Christopher R. Weber, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3364-3364
Open Access | Times Cited: 3
Finding a chink in the armor: Update, limitations, and challenges toward successful antivirals against flaviviruses
Thamil Vaani Komarasamy, Nur Amelia Azreen Adnan, William James, et al.
PLoS neglected tropical diseases (2022) Vol. 16, Iss. 4, pp. e0010291-e0010291
Open Access | Times Cited: 17
Identification of new small molecule monoamine oxidase-B inhibitors through pharmacophore-based virtual screening, molecular docking and molecular dynamics simulation studies
Sandeep Kumar, Senthil Raja Ayyannan
Journal of Biomolecular Structure and Dynamics (2022) Vol. 41, Iss. 14, pp. 6789-6810
Closed Access | Times Cited: 17
An overview of compound properties, multiparameter optimization, and computational drug design methods for PARP-1 inhibitor drugs
Bhakti Umesh Hirlekar, Anila Nuthi, Krishan Dev Singh, et al.
European Journal of Medicinal Chemistry (2023) Vol. 252, pp. 115300-115300
Closed Access | Times Cited: 9
Predicting Antifouling Activity and Acetylcholinesterase Inhibition of Marine-Derived Compounds Using a Computer-Aided Drug Design Approach
Susana P. Gaudêncio, Florbela Pereira
Marine Drugs (2022) Vol. 20, Iss. 2, pp. 129-129
Open Access | Times Cited: 15
Computational Identification of Possible Allosteric Sites and Modulators of the SARS-CoV-2 Main Protease
Debarati DasGupta, Wallace Chan, Heather A. Carlson
Journal of Chemical Information and Modeling (2022) Vol. 62, Iss. 3, pp. 618-626
Open Access | Times Cited: 14
The diverse role of heparan sulfate and other GAGs in SARS-CoV-2 infections and therapeutics
Friederike Eilts, Sarah Bauer, Keith Fraser, et al.
Carbohydrate Polymers (2022) Vol. 299, pp. 120167-120167
Open Access | Times Cited: 14
Machine learning prediction of 3CL SARS-CoV-2 docking scores
Lukáš Bučinský, Dušan Bortňák, Marián Gall, et al.
Computational Biology and Chemistry (2022) Vol. 98, pp. 107656-107656
Open Access | Times Cited: 11
Computational Repurposing of Drugs and Natural Products Against SARS-CoV-2 Main Protease (Mpro) as Potential COVID-19 Therapies
Sakshi Piplani, Puneet Kumar Singh, Nikolai Petrovsky, et al.
Frontiers in Molecular Biosciences (2022) Vol. 9
Open Access | Times Cited: 10
Discovery of C-12 dithiocarbamate andrographolide analogues as inhibitors of SARS-CoV-2 main protease: In vitro and in silico studies
Bodee Nutho, Patcharin Wilasluck, Peerapon Deetanya, et al.
Computational and Structural Biotechnology Journal (2022) Vol. 20, pp. 2784-2797
Open Access | Times Cited: 10
Garbage in, garbage out: how reliable training data improved a virtual screening approach against SARS-CoV-2 MPro
Santiago Matías Ruatta, Denis N. Prada Gori, Martín Fló, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 5
Ensemble docking based virtual screening of SARS‐CoV‐2 main protease inhibitors
Anastasiia D. Fomina, Victoria I. Uvarova, Liubov I. Kozlovskaya, et al.
Molecular Informatics (2024) Vol. 43, Iss. 8
Closed Access | Times Cited: 1
Molecular Dynamics Simulations in Drug Discovery
Onur Serçinoğlu, Xavier Chee Wezen, Ayesha Fatima
Elsevier eBooks (2024)
Closed Access | Times Cited: 1
Exploration of SARS-CoV-2 3CLpro Inhibitors by Virtual Screening Methods, FRET Detection, and CPE Assay
Jun Zhao, Qinhai Ma, Baoyue Zhang, et al.
Journal of Chemical Information and Modeling (2021) Vol. 61, Iss. 12, pp. 5763-5773
Closed Access | Times Cited: 10
Drug repurposing screening validated by experimental assays identifies two clinical drugs targeting SARS-CoV-2 main protease
Denis N. Prada Gori, Santiago Matías Ruatta, Martín Fló, et al.
Frontiers in Drug Discovery (2023) Vol. 2
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top